Perioperative Management of Patients With Drug-Eluting Stents

JACC: Cardiovascular Interventions

Volumn 3, Issue 2, 2010, Pages 131-142

  Abualsaud, Ali O ^a   Eisenberg, Mark J ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

antiplatelet therapy; drug eluting stent; noncardiac surgery; perioperative; stent thrombosis

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; E 5555; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLURBIPROFEN; HEPARIN; INDOBUFEN; PRASUGREL; PRT 060128; PURINERGIC RECEPTOR BLOCKING AGENT; SULFINPYRAZONE; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; TRIFLUSAL; UNCLASSIFIED DRUG; WARFARIN;

AGRANULOCYTOSIS; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ASPIRIN; CORONARY RESTENOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RISK FACTORS;

EID: 76449103429     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.11.017     Document Type: Review

References (119)

1. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 172-209
2. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
3. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
4. Hodgson J.M., Stone G.W., Lincoff A.M., et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv 69 (2007) 327-333
5. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implementation. JAMA 297 (2007) 159-168
6. Rodriguez A.E., Mieres J., Fernandez-Pereira C., et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol 47 (2006) 205-207
7. Ong A.T., McFadden E.P., Regar E., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
8. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
9. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
10. Update to FDA Statement on Drug-Eluting Stents. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/medsun/news/printer.cfm?id=575 Accessed January 5, 2010
11. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
12. Hasdai D., Garratt K.N., Holmes Jr. D.R., Berger P.B., Schwartz R.S., and Bell M.R. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 28 (1996) 361-367
13. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331 (1994) 496-501
14. Cutlip D.E., Baim D.S., Ho K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
15. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
16. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
17. Windecker S., and Meier B. Late coronary stent thrombosis. Circulation 116 (2007) 1952-1965
18. Eisenberg M.J., Richard P.R., Libersan D., and Filion K.B. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 119 (2009) 1634-1642
19. Gurbel P.A., DiChiara J., and Tantry U.S. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am J Cardiol 100 (2007) 18M-25M
20. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25 (2004) 166-181
21. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol 47 (2006) 2112-2115
22. Schuhlen H., Kastrati A., Dirschinger J., et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 98 (1998) 104-111
23. Luscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
24. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
25. Colombo A., and Corbett S.J. Drug-eluting stent thrombosis: increasingly recognized but too frequently overemphasized. J Am Coll Cardiol 48 (2006) 203-205
26. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
27. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
28. Ortolani P., Ardissino D., Cavallini C., et al. Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy). Am J Cardiol 96 (2005) 1393-1398
29. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
30. Auer J., Berent R., Weber T., and Eber B. Risk of noncardiac surgery in the months following placement of a drug-eluting coronary stent. J Am Coll Cardiol 43 (2004) 713 author reply 4-5
31. Satler L.F. Recommendations regarding stent selection in relation to the timing of noncardiac surgery postpercutaneous coronary intervention. Catheter Cardiovasc Interv 63 (2004) 146-147
32. Kaluza G.L., Joseph J., Lee J.R., Raizner M.E., and Raizner A.E. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 35 (2000) 1288-1294
33. Murphy J.T., and Fahy B.G. Thrombosis of sirolimus-eluting coronary stent in the postanesthesia care unit. Anesth Analg 101 (2005) 971-973
34. Artang R., and Dieter R.S. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol 99 (2007) 1039-1043
35. Schouten O., Bax J.J., Damen J., and Poldermans D. Coronary artery stent placement immediately before noncardiac surgery: a potential risk?. Anesthesiology 106 (2007) 1067-1069
36. Samama C.M., Thiry D., Elalamy I., et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 94 (2001) 74-78
37. Rosenfeld B.A., Beattie C., Christopherson R., et al. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology 79 (1993) 435-443
38. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252 (2002) 283-294
39. Priebe H.J. Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth 93 (2004) 9-20
40. Burger W., Chemnitius J.M., Kneissl G.D., and Rucker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 257 (2005) 399-414
41. Collet J.P., Montalescot G., Blanchet B., et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110 (2004) 2361-2367
42. Ferrari E., Benhamou M., Cerboni P., and Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45 (2005) 456-459
43. Head D.E., Sebranek J.J., Zahed C., Coursin D.B., and Prielipp R.C. A tale of two stents: perioperative management of patients with drug-eluting coronary stents. J Clin Anesth 19 (2007) 386-396
44. Nasser M., Kapeliovich M., and Markiewicz W. Late thrombosis of sirolimus-eluting stents following noncardiac surgery. Catheter Cardiovasc Interv 65 (2005) 516-519
45. Brown M.J., Long T.R., Brown D.R., and Wass C.T. Acute coronary syndrome and myocardial infarction after orthopedic surgery in a patient with a recently placed drug-eluting stent. J Clin Anesth 18 (2006) 537-540
46. Vicenzi M.N., Meislitzer T., Heitzinger B., Halaj M., Fleisher L.A., and Metzler H. Coronary artery stenting and non-cardiac surgery-a prospective outcome study. Br J Anaesth 96 (2006) 686-693
47. Wilson S.H., Fasseas P., Orford J.L., et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 42 (2003) 234-240
48. Sharma A.K., Ajani A.E., Hamwi S.M., et al. Major noncardiac surgery following coronary stenting: when is it safe to operate?. Catheter Cardiovasc Interv 63 (2004) 141-145
49. Reddy P.R., and Vaitkus P.T. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 95 (2005) 755-757
50. Schouten O., van Domburg R.T., Bax J.J., et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 49 (2007) 122-124
51. Brotman D.J., Bakhru M., Saber W., et al. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. J Hosp Med 2 (2007) 378-384
52. de Souza D.G., Baum V.C., and Ballert N.M. Late thrombosis of a drug-eluting stent presenting in the perioperative period. Anesthesiology 106 (2007) 1057-1059
53. Rabbitts J.A., Nuttall G.A., Brown M.J., et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 109 (2008) 596-604
54. Rhee S.J., Yun K.H., Lee S.R., et al. Drug-eluting stent thrombosis during perioperative period. Int Heart J 49 (2008) 135-142
55. Kim H.L., Park K.W., Kwak J.J., et al. Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent. Int J Cardiol 123 (2008) 353-354
56. Godet G., Le Manach Y., Lesache F., Perbet S., and Coriat P. Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem?. Br J Anaesth 100 (2008) 472-477
57. Assali A., Vaknin-Assa H., Lev E., et al. The risk of cardiac complications following noncardiac surgery in patients with drug eluting stents implanted at least six months before surgery. Catheter Cardiovasc Interv 74 (2009) 837-843
58. Compton P.A., Zankar A.A., Adesanya A.O., Banerjee S., and Brilakis E.S. Risk of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol 98 (2006) 1212-1213
59. Bertrand M.E., Rupprecht H.J., Urban P., and Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
60. von Mach M.A., Eich A., Weilemann L.S., and Münzel T. Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura. Heart 91 (2005) e14
61. Antman E.M., Hand M., Armstrong P.W., et al., Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, American Heart Association. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 210-247
62. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
63. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996) 1084-1089
64. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
65. Leon M.B., Baim D.S., Popma J.J., et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998) 1665-1671
66. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The CHARISMA trial. N Engl J Med 354 (2006) 1706-1717
67. Akowuah E., Shrivastava V., Jamnadas B., et al. Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. Ann Thorac Surg 80 (2005) 149-152
68. Murphy M.F., Brozovic B., Murphy W., Ouwehand W., Waters A.H., British Committee for Standards in Haematology, and Working Party of the Blood Transfusion Task Force. Guidelines for platelet transfusions. Transfus Med 2 (1992) 311-318
69. Sun J.C., Crowther M.A., Warkentin T.E., Lamy A., and Teoh K.H. Should aspirin be discontinued before coronary artery bypass surgery?. Circulation 112 (2005) e85-e90
70. Srinivasan A.K., Grayson A.D., Pullan D.M., Fabri B.M., and Dihmis W.C. Effect of preoperative aspirin use in off-pump coronary artery bypass operations. Ann Thorac Surgery 76 (2003) 41-45
71. Ferraris V.A., Ferraris S.P., Moliterno D.J., et al. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg 79 (2005) 1454-1461
72. Purkayastha S., Athanasiou T., Malinovski V., et al. Does clopidogrel affect outcome after coronary artery bypass grafting?. A meta-analysis. Heart 92 (2006) 531-532
73. Ascione R., Ghosh A., Rogers C.A., Cohen A., Monk C., and Angelini G.D. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 79 (2005) 1210-1216
74. Yende S., and Wunderink R.G. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 29 (2001) 2271-2275
75. Chu M.W., Wilson S.R., Novick R.J., Stitt L.W., and Quantz M.A. Does clopidogrel increase blood loss following coronary artery bypass surgery?. Ann Thorac Surg 78 (2004) 1536-1541
76. Leong J.Y., Baker R.A., Shah P.J., Cherian V.K., and Knight J.L. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 80 (2005) 928-933
77. Fox K.A., Mehta S.R., Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 (2004) 1202-1208
78. Payne D.A., Hayes P.D., Jones C.I., Belham P., Naylor A.R., and Goodall A.H. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg 35 (2002) 1204-1209
79. Chapman T.W., Bowley D.M., Lambert A.W., Walker A.J., Ashley S.A., and Wilkins D.C. Haemorrhage associated with combined clopidogrel and aspirin therapy. Eur J Vasc Endovasc Surg 22 (2001) 478-479
80. Ernst A., Eberhardt R., Wahidi M., Becker H.D., and Herth F.J. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 129 (2006) 734-737
81. Moore M., and Power M. Perioperative hemorrhage and combined clopidogrel and aspirin therapy. Anesthesiology 101 (2004) 792-794
82. Qureshi A.I., Saad M., Zaidat O.O., et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke 33 (2002) 1916-1919
83. Chassot P.G., Delabays A., and Spahn D.R. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99 (2007) 316-328
84. Howard-Alpe G.M., de Bono J., Hudsmith L., Orr W.P., Foex P., and Sear J.W. Coronary artery stents and non-cardiac surgery. Br J Anaesth 98 (2007) 560-574
85. Dalal A.R., D'Souza S., and Shulman M.S. Article de synthese court: Les tuteurs coronariens actifs et l'anesthesie [Brief review: coronary drug-eluting stents and anesthesia]. Can J Anaesth 53 (2006) 1230-1243
86. May A.E., Geisler T., and Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 99 (2008) 487-493
87. Broad L., Lee T., Conroy M., et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth 98 (2007) 19-22
88. Brilakis E.S., Banerjee S., and Berger P.B. Perioperative management of patients with coronary stents. J Am Coll Cardiol 49 (2007) 2145-2150
89. Newsome L.T., Weller R.S., Gerancher J.C., Kutcher M.A., and Royster R.L. Coronary artery stents: II. Perioperative considerations and management. Anesth Analg 107 (2008) 570-590
90. Albaladejo P., Marret E., Piriou V., and Samama C.M. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaesth 97 (2006) 580-582
91. The Scottish Intercollegiate Guidelines Network (SIGN). Management of stable angina. A National Clinical Guideline (February 2007). http://www.sign.ac.uk/pdf/sign96.pdf Accessed January 5, 2010
92. Elzayat E., Habib E., and Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175 (2006) 1428-1432
93. Sandhu J.S., Ng C.K., Gonzalez R.R., Kaplan S.A., and Te A.E. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 19 (2005) 1196-1198
94. Vicenzi M.N., Ribitsch D., Luha O., Klein W., and Metzler H. Coronary artery stenting before noncardiac surgery: more threat than safety?. Anesthesiology 94 (2001) 367-368
95. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331 (1994) 489-495
96. Dent H., Lekic Z., and Vicenzi M. Unfractionated heparin and coronary artery stenting. Br J Anaesth 97 (2006) 582 author reply 582
97. Frishman W.H., Burns B., Atac B., Alturk N., Altajar B., and Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 130 (1995) 877-892
98. Faulds D., and Sorkin E.M. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 48 (1994) 583-598
99. Kleiman N.S. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 138 (1999) 263-275
100. Bigalke B., Seizer P., Geisler T., Lindemann S., Gawaz M., and May A.E. Perioperative antiplatelet therapy in patients at risk for coronary stent thrombosis undergoing noncardiac surgery. Clin Res Cardiol 98 (2009) 335-339
101. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 234S-264S
102. Contreras M. Final statement from the consensus conference on platelet transfusion. Transfusion 38 (1998) 796-797
103. Hay A., Olsen K.R., and Nicholson D.H. Bleeding complications in thrombocytopenic patients undergoing ophthalmic surgery. Am J Ophtalmol 109 (1990) 482-483
104. Jarvis B., and Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 60 (2000) 347-377
105. Miller R.D. Transfusion therapy. In: Miller R.D., Eriksson L.I., Fleisher L.A., Wiener-Kronish J.P., and Young W.L. (Eds). Miller's Anesthesia. 7th edition (2009), Churchill Livingstone, Philadelphia, PA 1760 55:
106. Samama C.M., Djoudi R., Lecompte T., Nathan-Denizot N., and Schved J.F. Perioperative platelet transfusion: recommendations of the Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSaPS) 2003. Can J Anaesth 52 (2005) 30-37
107. Eto K., Goto S., Shimazaki T., et al. Two distinct mechanisms are involved in stent thrombosis under flow conditions. Platelets 12 (2001) 228-235
108. FDA Approves Effient to Reduce the Risk of Heart Attack in Angioplasty Patients (2009). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm171497.htm Accessed January 5, 2010
109. Angiolillo D.J., and Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 156 (2008) S10-S15
110. Weerakkody G.J., Jakubowski J.A., Brandt J.T., et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 100 (2007) 331-336
111. Weerakkody G.J., Jakubowski J.A., Brandt J.T., Payne C.D., Naganuma H., and Winters K.J. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 12 (2007) 205-212
112. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
113. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
114. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., and Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 (2006) 1038-1047
115. Cannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50 (2007) 1844-1851
116. Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 (2007) 1852-1856
117. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009) 1045-1057
118. Zeidner J.F., Frishman W.H., and Lerner R.G. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. Cardiol Rev 16 (2008) 250-259
119. Cangrelor: Product Overview. The Medicines Company (2009). http://www.themedicinescompany.com/products_cangrelor.shtml Accessed January 5, 2010